Erosion risks

• Plain packaging and marketing restrictions reduce brand differentiation
• Accelerating volume declines from health trends and regulation
• Downtrading to deep-discount brands (and illicit trade)

Leading indicators

• Price/mix vs industry inflation
• Strategic brand volume mix (%)
• Retail price gaps vs discount/illicit alternatives

Counterarguments

• Many markets restrict branding, making products closer to commodity
• Price increases can accelerate consumer downtrading and switching

Erosion risks

• Consolidation of large retailers increases buyer power
• Regulatory limits on retail display reduce merchandising advantages
• Illicit trade bypasses formal retail channels

Leading indicators

• Retail coverage and out-of-stock rates in key markets
• Channel mix shifts (duty-free vs domestic, modern trade vs traditional)
• Enforcement intensity against illicit trade

Counterarguments

• Route-to-market capabilities are shared by other large incumbents
• In some markets, state-controlled distribution reduces differentiation

Erosion risks

• Adverse regulation (nicotine caps, flavor bans, tax hikes)
• Litigation and settlements
• Regulatory-driven shift toward reduced-risk alternatives

Leading indicators

• Major regulatory proposals and implementation timelines
• Compliance cost trend and enforcement actions
• Share of volume shifting to illicit channels

Counterarguments

• Regulation can also compress industry profitability and limit pricing/marketing
• New illicit/gray-market entrants can still bypass compliance

Erosion risks

• Consumers can switch between devices if products commoditize
• Open-system and disposable formats reduce lock-in
• Illicit products displace legal devices/consumables

Leading indicators

• Consumables share and repeat-purchase rates
• Device installed-base growth (active users)
• Share of category volume shifting to disposables/illicit

Counterarguments

• Many consumers are price-sensitive and can churn quickly
• Hardware differentiation is hard to sustain; clones and substitutes proliferate

Erosion risks

• Adverse regulation (flavor restrictions, product bans)
• PMTA denials or litigation outcomes limiting product line
• Policy shifts that weaken enforcement against illicit products

Leading indicators

• FDA authorisations/denials and court outcomes
• State-level 'vapour directory' rollout and enforcement
• Illicit market share estimates and seizure activity

Counterarguments

• Enforcement gaps allow non-compliant competitors to dominate
• Authorization alone may not translate into profitability if price pressure persists

Erosion risks

• Brand equity erodes if illegal products dominate consumer preference
• Product quality/safety issues harm trust
• Rapid innovation cycles narrow differentiation

Leading indicators

• Tracked-channel value share (U.S. and Top markets)
• Net pricing vs volume trend
• Customer complaint/quality metrics and recalls

Counterarguments

• High share in tracked channels may understate the true market if illicit dominates
• Brand loyalty is weaker than in cigarettes; consumers chase flavors and price

Erosion risks

• Competitor ecosystems (e.g., IQOS) dominate consumer mindshare and retail space
• Regulatory restrictions on heated products and flavors
• Device commoditization reduces differentiation

Leading indicators

• Active users / consumer acquisition
• Consumable volume per user
• Category share in Top markets

Counterarguments

• Switching costs can be low if devices are subsidized or easily replaced
• Retail availability and taxation can matter more than brand/device preference

Erosion risks

• Feature parity reduces perceived differentiation
• Negative publicity about device safety or health impacts

Leading indicators

• Brand awareness and repeat purchase rates
• Device NPS / satisfaction metrics

Counterarguments

• Category is still early and price/tax dynamics can outweigh brand

Erosion risks

• Regulators restrict claims or impose product standards
• Litigation and health controversies

Leading indicators

• Regulatory policy changes in key HP markets
• Acceptance of reduced-risk frameworks and claims

Counterarguments

• Science spend is necessary but not sufficient; market outcomes driven by consumer preference and taxation

Erosion risks

• Dominant competitors with stronger scale/brand in pouches
• Flavor or nicotine strength restrictions
• Price competition and promotions to win share

Leading indicators

• Volume share in top markets
• Net revenue per pouch / price-mix trend
• Distribution expansion (stores/markets carrying Velo)

Counterarguments

• Nicotine pouch products can be hard to differentiate; consumers may multi-home by flavor/price
• Category growth may attract many entrants, diluting brand advantages

Erosion risks

• Input cost inflation (ingredients, packaging)
• Quality incidents or recalls
• Competitors match manufacturing standards

Leading indicators

• Manufacturing yield/complaint rates
• Capacity expansions and utilization
• Regulatory inspection outcomes (where applicable)

Counterarguments

• Manufacturing excellence is replicable and may not translate to market share without superior branding and distribution

Erosion risks

• PMTA outcomes constrain product assortment
• Tax policy shifts reduce category economics

Leading indicators

• FDA actions and policy signals on oral nicotine
• PMTA progress and authorisations/denials

Counterarguments

• Regulatory uncertainty can slow category growth and compress returns for all incumbents

Erosion risks

• Cross-category switching to nicotine pouches (Modern Oral)
• Macro-driven downtrading reduces premium mix
• Regulatory actions on smokeless products

Leading indicators

• U.S. category volume trend and trade-down indicators
• Brand share vs key rivals
• Net pricing vs volume declines

Counterarguments

• Brand loyalty is weaker when consumers substitute across oral formats
• Category decline can overwhelm brand advantages

Erosion risks

• Retailer consolidation increases slotting/buyer power
• Shift toward online/direct channels changes economics

Leading indicators

• Numeric distribution and shelf space in key U.S. channels
• Trade spend intensity

Counterarguments

• Distribution advantages are shared by other large incumbents in U.S. tobacco

Erosion risks

• Adjacent markets are crowded with faster-moving consumer brands
• Capabilities may not transfer; marketing and product-market fit dominate
• Regulatory regimes differ across categories

Leading indicators

• Revenue contribution and gross margin from 'Other'
• Repeat purchase/retention metrics for new products
• Distribution wins in targeted channels

Counterarguments

• Incumbency in tobacco does not guarantee success in new FMCG categories
• Category leaders can outspend and out-innovate in branding